Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:AZRX

AzurRx BioPharma (AZRX) Stock Price, News & Analysis

AzurRx BioPharma logo

About AzurRx BioPharma Stock (NASDAQ:AZRX)

Key Stats

Today's Range
$0.63
$0.72
50-Day Range
$2.40
$41.00
52-Week Range
$3.36
$26.30
Volume
93,033 shs
Average Volume
628,703 shs
Market Capitalization
$6.29 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

AzurRx BioPharma, Inc. engages in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. Its product programs include MS1819, FW-1022: COVID-19 GI infections, and FW-420: Immune Checkpoint Inhibitor Colitis. The company was founded on January 30, 2014 and is headquartered in Delray Beach, FL.

Receive AZRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AzurRx BioPharma and its competitors with MarketBeat's FREE daily newsletter.

AZRX Stock News Headlines

Entero Therapeutics Inc (ENTO)
YS YS Biopharma Co., Ltd.
Elon knows the truth, which is why they want him silenced
Elon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to humanity, there is a war being waged on Elon Musk. This war has nothing to do with X, Elon’s stance on immigration.
FWBI First Wave BioPharma, Inc.
First Wave BioPharma Inc (FWBI)
First Wave BioPharma Inc
See More Headlines

AZRX Stock Analysis - Frequently Asked Questions

Shares of AzurRx BioPharma reverse split before market open on Monday, September 13th 2021. The 1-10 reverse split was announced on Monday, September 13th 2021. The number of shares owned by shareholders was adjusted after the closing bell on Monday, September 13th 2021. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

AzurRx BioPharma (AZRX) raised $15 million in an initial public offering (IPO) on Friday, September 9th 2016. The company issued 2,100,000 shares at $6.00-$8.00 per share. WallachBeth Capital and Network 1 Financial Securities acted as the underwriters for the IPO.

Based on aggregate information from My MarketBeat watchlists, some other companies that AzurRx BioPharma investors own include SCYNEXIS (SCYX), Acasti Pharma (ACST), Sorrento Therapeutics (SRNE), Tonix Pharmaceuticals (TNXP), Vaxart (VXRT), Inovio Pharmaceuticals (INO) and Novavax (NVAX).

Company Calendar

Today
11/04/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:AZRX
Fax
N/A
Employees
12
Year Founded
N/A

Profitability

Net Income
$-32,670,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
($0.76) per share

Miscellaneous

Free Float
8,645,000
Market Cap
$6.42 million
Optionable
Not Optionable
Beta
1.51
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

This page (NASDAQ:AZRX) was last updated on 11/4/2024 by MarketBeat.com Staff
From Our Partners